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Cationic carbosilane dendrimers and
oligonucleotide binding: an energetic aﬀairQ1 †
D. Marson,‡a E. Laurini,‡a P. Posocco,a,b M. Fermegliaa and S. PriclQ2 *a,b
Generation 2 cationic carbosilane dendrimers hold great promise as internalizing agents for gene therapy
as they present low toxicity and retain and internalize the genetic material as an oligonucleotide or siRNA.
In this work we carried out complete in silico structural and energetical characterization of the inter-
actions of a set of 2G carbosilane dendrimers, showing diﬀerent aﬃnity towards two single strand oligo-
nucleotide (ODN) sequences in vitro. Our simulations predict that these four dendrimers and the relevant
ODN complexes are characterized by similar size and shape, and that the molecule-speciﬁc ODN binding
ability can be rationalized only by considering a critical molecular design parameter: the normalized
eﬀective binding energy ΔGbind,eﬀ/Neﬀ, i.e. the performance of each active individual dendrimer branch
directly involved in a binding interaction.
Introduction
Molecular nano(bio)technology pertains to either synthetic or
natural systems, which have nanoscale dimensions or func-
tioning nanoscale components, ultimately resulting in novel
and unique material properties. This branch of science cur-
rently occupies a flourishing niche in medicine, known as
nanomedicine,1 particularly within the field of controlled
drug/gene delivery. A major, potential benefit of nanomedicine
is the design of nanovectors able to deliver their therapeutic
cargoes at the required dosage and to the site of lesion, thus
maximizing selective eﬀects thereby minimizing toxicity.2
Truly speaking, the achievement of such ideal nanovectors still
remains a sort of chimera, as these nanocarriers and their pay-
loads have to face an aptly organized array of biological barri-
ers along their way to their target site.3 Eﬃcient nanoparticle
transport across biological barriers and within diﬀerent cell
compartments is strongly influenced by the nanovector size,
shape, density and surface chemistry and charge. The blend of
all these molecular parameters masters the nanovector circula-
tion in the bloodstream, margination, cell membrane
adhesion and uptake and, eventually, intracellular traﬃcking.4
The overall, multidisciplinary complexity characterizing nano-
vector design, coupled with the fervent activity in the field, has
resulted in a plethora of nanovectors for drug or gene delivery
currently investigated being at the pre-clinical or clinical
stage.5
Gene therapy holds momentous potential for therapeutic
intervention in a broad range of genetic maladies, including
infectious diseases, gene-related disorders, and cancer. Gene
therapy involves intracellular transfer of nucleic acid material
to modulate cell functions and responses by expressing
exogenous proteins, by silencing a specific gene, or by editing
undesirable genomic mutations. Regrettably, most nucleic
acids as such not only experience transport problems across
the cell membranes but also are subjected to rapid recognition
and enzymatic digestion by nucleases. Therefore, appropriate
nanovectors able to eﬃciently allow genetic material to reach
the desired population of cells, cross their membranes, dis-
charge the exogenous nucleic acid safely and eﬃciently to
bring out maximum therapeutic eﬀects are highly needed.6
Among diﬀerent molecular systems available for the
purpose, dendrimers play the leading role as premiere nano-
carriers, especially in gene delivery.7 Indeed, they provide great
gene loading capacity, well-defined physico-chemical pro-
perties, and a high degree of molecular diversity that allow
extensive modification to help overcome extracellular and
intracellular barriers to gene delivery. Specifically, cationic
dendrimers such as the renowned poly(amidoamine) dendri-
mers or PAMAMs, are cationic in nature, in that they contain
several amine groups that, according to their nature (primary
or tertiary), become protonated at two major physiological pH
values (i.e., 7.4 and 5). The interaction of the positively
charged dendrimer nanocarriers and the negatively charged
nucleic acid results in the spontaneous formation of nano-
sized complexes – termed polyplexes – in a physiological
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environment. The neutral character of these compact nano-
objects helps in protecting the genetic cargo from nuclease
attack and ensures stability to the nanovector/cargo ensemble
during cellular uptake. Once inside the cell, the ideal dendri-
mer nanovectors should be able to escape from the endosomal
compartment and finally unload their nucleic acid cargo into
the cytoplasm. Understanding the critical barriers of gene
delivery to cells is a prerequisite for the rational design of
eﬃcient nanocarriers. Only with that information in hand,
new nanovector systems can be carefully designed and their
properties can be fine-tuned to achieve the optimal transfec-
tion eﬃciency along with the desired clinical success.
The recent developments in the fight against the HIV infec-
tion have seen the flourishing new anti-viral drugs which,
unfortunately, were all dropped in phase II or III trials due to
severe toxicity problems and the insurgence of the drug-resist-
ance phenomenon.8 Another serious problem faced by HIV
antivirals is constituted by the inherent diﬃculty to reach the
target cells (particularly the central nervous system) and their
inability to eradicate the latently infected cells. Gene therapy
represents a possible, alternative approach to HIV infection
treatment, holding promise for a higher eﬃciency in selec-
tively killing infected cells and cleaning viral reservoirs while
abating deleterious side eﬀects.9 Specifically, short oligo-
nucleotides (ODNs) constitute a class of antisense therapy drugs
not only in HIV control but also in the treatment of cancer and
other infectious or metabolic dysfunctions.10 For instance, the
25-base ODN GEM91 binds to the translation initiation site of
the gag gene of the HIV-1 pathogen of acquired immunodefi-
ciency able to inhibit virus entry/reverse transcription and to
reduce steady state viral RNA levels. Similarly, the rev gene is
involved in the regulated expression of HIV structural genes, as
rev mutants of HIV-1 are incapable of inducing the synthesis
of the viral structural proteins gag, pol, and env, and are there-
fore replication defective. The antisense ODN referred to as
SREV is of suﬃcient length and complementarity to inhibit
the expression of the rev gene and, hence, to halt viral
replication.
However, as discussed above, ODN delivery requires an
eﬃcient carrier to reach the target cells eﬃciently and safely.
Moreover, by virtue of their high anionic charge, ODNs show a
remarkable tendency to bind to serum proteins (e.g., human
serum albumin).11 This results in a lower ODN bioavailability,
and hence requires higher ODN doses to reach the expected
therapeutic eﬀect. Both non-specific serum protein binding
and dose elevation can in turn induce toxic side eﬀects, which
ultimately results in an overall lower-than-expected perform-
ance of the ODN therapeutic option.
Muñoz-Fernandez et al. have recently shown12 that gene-
ration 2 (G2) cationic carbosilane dendrimers, containing
ammonium or amine groups in their molecular architecture,
could be used as internalizing agents for gene therapy as they
present low toxicity, retain and internalize genetic material as
oligonucleotides or siRNA. Among this water-soluble carbosi-
lane dendrimer family, compounds 2G-[Si(OCH2CH2-
NMe3+I−)]8 (1), 2G-[Si(OCH2CH2NMe3+I−)2]8 (2), 2G-[Si{O(CH2)2N(Me)-
(CH2)2NMe3+I−}]8 (3), and 2G-[Si{O(CH2)2N(Me)2+(CH2)2-
NMe3+-(I−)2}]8 (4) (Fig. 1) were thoroughly characterized for
their capacity of binding to diﬀerent ODNs and serum proteins
and, most importantly, for their ability to transfect normal
primary peripheral blood cells and inhibit HIV-1 replication in
the presence of serum.12
Further studies concerning the use of 1–4 as potential carri-
ers for gene delivery or for other biomedical applications
gave encouraging results. Indeed, distinct (but complemen-
tary) approaches employed to evaluate membrane integrity,
metabolic activity, apoptosis, morphology, and cell movement
all revealed that all carbosilane dendrimers are endowed with
good toxicity profiles in cell cultures over extended periods.12
Most importantly, in spite of their low generation number,
these carbosilane dendrimers were shown to form complexes
with DNA oligonucleotides (ODNs) or even with plasmids at
biocompatible doses. In addition, the presence of Si–O bonds
in their structure open the way for the use of these molecules
as drug delivery systems by exploiting the corresponding
hydrolytic process. However, in a dedicated study it was veri-
fied that while dendrimers 2–4 could eﬀectively bind GEM91
and SREV (two short ODNs currently employed as antisense
antivirals in HIV-1 treatment), dendrimer 1 showed a remark-
ably low aﬃnity for the nucleic acid with respect to the other
members of the molecular family (aﬃnity decreasing in the
order 4 ≥ 3 > 2 ≫ 1).13 Also, the same study showed that the
ODN aﬃnity of all dendrimers 1–4 appeared somewhat higher
for the ODN GEM 91 with respect to that exhibited towards the
alternative ODN sequence SREV.
Hence, starting from the very first challenge in nanovector
design – the eﬃcient interaction of a nanocarrier with its
cargo – in this work we aimed at determining the reasons for
this diﬀerential behavior among these 4 carbosilane dendri-
mers in binding GEM91 and SREV ODNs. To this goal, we per-
formed a thorough in silico characterization of the structural
Fig. 1 Structure of the 2G carbosilane dendrimers 1–4. Each dendrimer
branch is labeled for per residue binding free energy decomposition
purposes (see Results and discussion).
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features of these molecules coupled with an energetic analysis
of the corresponding polyplexes.
Interestingly, we found that while all compounds were
characterized by similar size and shape, the molecule-specific
ODN binding ability could be rationalized considering the
normalized eﬀective binding energy ΔGbind,eﬀ/Neﬀ, i.e. the per-
formance of each active individual dendrimer branch directly
involved in a binding interaction.
Simulation methods
Initial model building and refinement
All simulations discussed in this work were carried out using
the AMBER14 suite of programs14 and performed with the
GPU version of pmemd, pmemd.cuda, from AMBER14 on the
EURORA GPU-CPU supercomputer (CINECA, Bologna, Italy).
The four carbosilane dendrimer models were built, parameter-
ized and refined following a consolidated procedure described
in detail in our previous work.15 Briefly, the 3D structure of
each dendrimer was built and geometry-optimized using the
Antechamber module of AMBER14 consistently with the
General Amber Force Field (GAFF).16 Eventually missing force
field terms were derived from quantum mechanical calcu-
lations using the GAMESS software17 and the paramfit of
AMBER14. For QM calculations, the MP2/HF/6-31G level of
theory was used. van der Waals parameters for Si were taken
from the MM3 force field.18 Partial charges were obtained via
the resp program implemented in AMBER14. The ODN models
for GEM91 (sequence CTC TCG CAC CCA TCT CTC TCC TTC T)
and SREV (sequence TCG TCG CTG TCT CCG CTT CTT CTT
GCC A) were built with the tleap routine of AMBER14. The
force field ﬀ12SB was adopted for optimizing the structure of
the two ODNs.
The structures of each dendrimer and ODN were immersed
in a box of TIP3P water molecules.19 The dimension of each
simulation box was chosen in order to ensure a 1 nm solvation
shell around each solute structure. Suitable amounts of Na+
and Cl− ions required to achieve solution neutrality and to
realize a physiological ionic strength of 0.15 M were added to
each system. The resulting hydrated structures were then sub-
jected to an initial Steepest Descent (SD)/Conjugated Gradient
(CG) minimization with 5.0 kcal (mol Å2)−1 restraint on the
solute (solvent relaxation), followed by another round of CG
minimization without restraints in order to eliminate all bad
contacts between water molecules and the dendrimer/ODN
structure.
Next, each minimized structure was subjected to molecular
dynamics (MD) simulations in the canonical ensemble (con-
stant volume/constant temperature, or NVT). During this
100 ps MD, each system was gradually heated and relaxed to
300 K. The SHAKE algorithm20 was applied to all covalent
bonds involving hydrogen atoms. An integration time step of
2 fs was adopted together with the Langevin thermostat for
temperature regulation (collision frequency = 2.0 ps−1).21
The final heating step was followed by 50 ns of MD
equilibration in the isochoric/isothermal (NPT) ensemble.
Pressure control was exerted by coupling the system to a
Berendsen barostat (pressure relaxation time 2 ps).22 The
particle Mesh Ewald (PME)23 method was used to treat long-
range electrostatic interactions under periodic conditions with
a direct space cut-oﬀ of 10 Å. A frame from each equilibrated
MD trajectory of the dendrimers and ODN was extracted
to build diﬀerent carrier/nucleic acid complex initial
configurations.
For the construction of the dendrimer/ODN complex
models, we resorted to a novel procedure based on Steered
Molecular Dynamics (SMD) simulations.24 Specifically, the
equilibrated dendrimer and ODN structures extracted from the
corresponding equilibrated MD simulations were placed 60 Å
away from each other in a solvated box. Next, the dendrimer
was pulled close to its target using a force of 50 kcal (mol Å2)−1
and a velocity of 5 Å ns−1. The phosphorous atoms of the ODN
were forced in their position by applying a weak restraint of
0.5 kcal (mol Å2)−1. This allowed avoiding substantial defor-
mation of the ODN during the dendrimer pulling process.
Once the dendrimer reached the proximity of the ODN (i.e.,
distance between the dendrimer and the ODN center of mass
approximately 12 Å), this restraint was released and both mole-
cules were allowed to move to reach the final complex
configuration.
Each resulting dendrimer/ODN complex was again equili-
brated for 50 ns of equilibration in the NPT ensemble and,
starting from the last equilibrated frame, we next performed
further 50 ns of simulation in an NVT ensemble for data col-
lection and analysis.
Structural analysis
The structural analysis of the dendrimers per se and in
complex with the two ODNs was performed using the cpptraj
program of AMBER14. Further calculations were carried out
using in-house developed python scripts. If not diﬀerently
stated, all structural data discussed represent values averaged
over the last 40 ns of the production runs, with MD trajectory
snapshots taken every 40 ps.
Free energy of binding
The dendrimer/ODN free energy of binding ΔGbind was derived
following our thoroughly validated methodology15 based on
the Molecular Mechanics/Poisson Boltzmann Surface Area
(MM/PBSA) approach.25 This computational technique
employs snapshots taken from MD trajectories to estimate the
average interaction energies based on the solute molecular
mechanics internal energy (ΔEMM) and solvation energy
(ΔGsolv), the latter obtained via Poisson–Boltzmann (PB) conti-
nuum solvent calculations. According to MM/PBSA, the overall
binding energy ΔGbind is given by the diﬀerence in energy
between the dendrimer/ODN complex and the individual
dendrimer and ODN:
ΔGbind ¼ ΔGcomplex " ΔGdendrimer " ΔGODN ð1Þ
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ΔGbind ¼ ΔEMM þ ΔGsolv " TΔS ð2Þ
ΔEMM ¼ ΔEint þ ΔEvdW þ ΔEele ð3Þ
ΔEint ¼ ΔEbond þ ΔEangle þ ΔEtors ð4Þ
ΔGsolv ¼ ΔGPB þ ΔGnp ð5Þ
ΔEMM is the system change in molecular mechanical energy
upon binding, which consists of internal energy ΔEint (due to
bonds, angles, and dihedral angle variations), electrostatic
energy (ΔEele) and van der Waals (ΔEvdW) contributions. The
solvation energy term ΔGsolv consists of two components: the
electrostatic term ΔGPB and the nonpolar term ΔGnp. ΔGPB is
obtained by solving the Poisson–Boltzmann equation while
ΔGnp can be obtained via the semi-empirical expression: ΔGnp =
γ × SASA + β, in which SASA is the solvent accessible surface
area of the molecule, γ is the surface tension parameter
(0.00542 kcal Å−2 mol−1), and β = 0.92 kcal mol−1. Finally, the
entropic contribution −TΔS is calculated via normal mode of
harmonic frequencies obtained from a subset of minimized
snapshots taken from the corresponding MD trajectories.
In this work, we adopted the so-called “multi-trajectory
approach”, wherein the bound and unbound states of the den-
drimers and the ODNs are simulated separately, in contrast to
the widely adopted “single trajectory” procedure. This choice
was dictated by the necessity for eﬀectively sampling the
unbound state of the dendrimer and the ODN for free energy
calculations. The single trajectory method is indeed appropri-
ate for those systems in which the molecules do not undergo
substantial conformational changes upon binding, which is
not the case for the compounds of interest in the present
work.
The analysis of the energy of interactions between the
dendrimers and the ODNs was accomplished with the
MMPBSA.py script implemented in AmberTools14. Energy
values were averaged over 200 frames taken during an equally
spaced time interval during the last 15 ns of the MD pro-
duction steps. Normal mode analysis was carried out on a
subset of 15 minimized MD snapshots evenly extracted from
the relevant trajectory time frame used for energy calculations.
Finally, the eﬀective number of charges involved in
binding, and the corresponding eﬀective free energy of
binding values were obtained performing a per residue binding
free energy decomposition exploiting the MD trajectories of
each given dendrimer/ODN ensemble.26 This analysis
was carried out using the MM/GBSA approach,27 and was
based on the same snapshots used in the binding free energy
calculations.
Results and discussion
Structural aspects of G2 carbosilane dendrimers 1–4
To characterize the structure and properties of these dendri-
mers, we have selected the following quantities: (i) radius of
gyration Rg; (ii) solvent accessible surface area SASA; (iii) shape
tensor S; (iv) molecular asphericity δ; and (v) monomer density
distribution ρ(r).
A parameter that provides a quantitative characterization of
the size of a molecule is the radius of gyration Rg. For a given










where R is the center of mass of the dendrimer, ri and mi are
the position and mass of the ith atom, and M is the total mass
of the dendrimer.
Table 1 lists the values of Rg obtained from equilibrated
MD trajectories of 1–4 in water at 0.15 mM NaCl. As we see,
dendrimers 1 and 3, both characterized by 8 positive charges
on their surface (Fig. 1), have similar values of Rg. (9.07 and
9.92 Å, Table 1). As somewhat expected, the two other dendri-
mers 2 and 4 bearing 16 positive charges on their scaﬀolds
have larger dimensions with respect to their less charged
counterparts (10.39 and 10.62 Å, Table 1). Interestingly,
however, the diﬀerent molecular architecture of 2 and 4 (con-
taining 8 groups of single and doubly methylated outer frag-
ments, respectively, Fig. 1) does not result in a significant
diﬀerence in their Rg values.
Considering the lowest generations of the most popular
dendrimer family, the ethylenediamine-core (EDA) poly(amido-
amine)s or PAMAMs, as a proof-of-concept for comparison,
it is interesting to observe that the literature Rg values for the
G1-PAMAM, with 8 positively charged terminal groups at pH
7.4, fall in the interval 7.5–9.9 Å, while those for the G2-
PAMAM, with 16 charged terminal groups at physiological pH
range from 9.2 to 13.6 Å.28 Notwithstanding the well-known
literature controversy about Rg values for PAMAM dendrimers,
we are tempted to observe that, on average, the calculated Rg
values of all G2 carbosilane dendrimers 1–4 fall in an inter-
mediate range of dimensions between G1- and G2-PAMAMs.
The comparison between G2 carbosilanes 2 and 4, and the
G2-PAMAM is straightforward: both G2 dendrimer families
feature 16 positive charges in their outer shell and are charac-
terized by similar values of atom numbers (N) and solvent
accessible surface areas (SASA). Indeed, N = 489, 481, and 532
and SASA = 2699, 2555, and 2333 Å2 for 2, 4, and G2-PAMAM,
respectively (Table 1 and ref. 28). The results for the carbosi-
lane dendrimers 1 and 3 can be rationalized by considering
that these two molecules do bear the same charge of G1-
Table 1 Number of atoms N (−), radius of gyration Rg (Å), asphericity δ
(−), and solvent accessible surface area SASA (Å2) of dendrimers 1–4
N Rg δ SASA
1 361 9.07 ± 0.21 0.0126 1910 ± 87
2 489 10.39 ± 0.13 0.0096 2699 ± 76
3 449 9.92 ± 0.28 0.0174 2288 ± 82
4 481 10.62 ± 0.25 0.0103 2555 ± 72
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PAMAM (+8) but, being a generation 2, they are also character-
ized by a number of atoms and, accordingly, a solvent accessi-
ble surface area quite larger than those pertaining to
G1-PAMAM. In fact, while N = 361 and 489 for 1 and 3,
respectively (Table 1), the N value for a EDA-core G1 PAMAM is
236; in line with this, the calculated SASA for G1 PAMAM is
quite smaller (1341 Å)28 than the corresponding SASA values
obtained for 1 and 3 (1910 and 2288 Å2, Table 1). This
evidence supports the fact that the Rg values of 1 and 3 lie in
the upper limit of the G1-PAMAM interval.
Concerning the shape of G2 carbosilane dendrimers 1–4,
the first, qualitative clue is provided by Fig. 2, showing snap-
shots extracted from the corresponding equilibrated MD
trajectories. From these images we see that, at variance with
the reference G2 PAMAMs that are characterized by a highly
asymmetrical conformation,28 all 1–4 molecules are character-
ized by a symmetrical, nearly spherical shape.
A quantitative support to this qualitative assertion is








# $% & ð7Þ
where ri is the position of the ith atom with respect to the
center of mass of the molecule and 13 is the unitary matrix
of dimension 3. Transformation to the principal axis system
diagonalizes S (S = diag(Ix,Iy,Iz)), and the three eigenvalues
of S (Iz, Iy, and Ix, sorted in the descending order) are the
principal moments of inertia of the equivalent ellipsoid. The
first invariant of S gives the squared radius of gyration (Tr S =
Ix + Iy + Iz = Rg2) while the second invariant shape descriptor,
or the asphericity δ, reflects the deviation from a spherical
shape of a molecular conformation:29
δ ¼ 1" 3 kI2l
kI21 l
ð8Þ
where I1 and I2 refer to the first and second invariants of the
shape tensor:
I1 ¼ Ix þ Iy þ Iz ð9Þ
I2 ¼ IxIy þ IyIz þ IxIz ð10Þ
Fig. 3 shows the moment of inertia-based molecular aspect
ratios and the asphericity parameter δ for the G2 carbosilane
dendrimers 1–4 as obtained from the corresponding equili-
brated MD trajectories. We see that for all dendrimers both
aspect ratios Iz/Ix and Iz/Iy are in the range 1.0–1.7, indicating
that these molecules are strongly compact spheroids indepen-
dent of their charge (+8/+16). In keeping with this, the aspheri-
city parameter δ values are all quite small and close to zero
(Fig. 3 and Table 1 for numerical values), confirming the
spherical character of these dendrimer conformations.
At variance with EDA-core PAMAMs, for which lower gene-
ration molecules (G1–G3) tend to assume highly asymmetrical
shapes whereas higher generations (G5–G7) become nearly
spherical, G4 being a transition between the two forms,28 the
carbosilane dendrimers 1–4 already attain a spherical distri-
bution of mass at G2. Aside from eventual small diﬀerences in
their branch flexibility and/or hydrophilicity, this diﬀerence
can be essentially attributed to the geometry of the core.
Indeed, we know that the size, shape, and initiator-core multi-
plicity Nc exert a dramatic influence on the ultimate critical
molecular design parameters (CMDPs)30 of a dendrimer. Thus,
although for both dendrimer families Nc = 4, the initiator-core
for the G2 carbosilane dendrimers consists of a single, Si atom
from which the four branches emanate directly and radially in
space. In contrast, in the case of the EDA-based PAMAMs the
core consists of a small, flexible, 4 atom-long chain, to which
the dendrons are tethered and extend from its extremes. As the
initiator-core is a dendrimer primary template, these diﬀer-
ences are transcribed and displayed through the dendrimer
development; thus, the carbosilane dendrimers 1–4 are already
spherical at lower generations while higher generation
Fig. 3 Moment of inertia-based aspect ratios (left) and asphericity para-
meter δ (right) for the G2 carbosilane dendrimers 1–4 generated from
the corresponding equilibrated MD trajectories.
Fig. 2 Zoomed view of equlibrated MD snapshots of G2 carbosilane
dendrimers 1 (top left), 2 (top right), 3 (bottom left), and 4 (bottom
right). In all panels, the dendrimers are shown as colored sticks (1, light
blue; 2, dark sea green, 3, plum; 4, dark lavender), water is portrayed as
light gray transparent spheres, and some Na+ and Cl− ions are depicted
as purple and green spheres, respectively. Hydrogen atoms are omitted
for clarity.
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numbers are required for EDA-core PAMAMs to fold into a
sphere.
The average radial monomer density ρ(r) can provide infor-
mation about the internal structure of the simulated dendri-
mers. ρ(r) can be defined as the number of atoms whose
center of mass is located within a spherical shell of radius r
and thickness Δr. Accordingly, integration over r yields the
total number of atoms N(R) as
N Rð Þ ¼ 4π
ðR
0
r2ρ rð Þdr ð11Þ
Fig. 4 shows the overall radial density profiles for the G2
carbosilane dendrimers 1–4, calculated taking the origin as
the center of mass of the dendrimer (see also Fig. SI1† for
details). As we see, all dendrimers are characterized by almost
superimposable profiles indicative of a rather uniform space
filling: the curves spike at small R, and then almost monotoni-
cally decrease, the width of the tail zone being again very
similar for all 4 dendrimers. This is a further confirmation of
the fact that the same branching pattern and, above all, the
presence of a tetravalent Si atom as the common initiator-core
for these G2 carbosilane dendrimers dictate the overall,
similar conformation of these molecules.
Complexation of G2 carbosilane dendrimers with ODNs
Given the similarities in size and shape shared by G2 carbosi-
lanes 1–4, in order to explain the diﬀerence in binding
aﬃnities of the four dendrimers for the two ODN sequences
GEM91 and SREV we went on and performed MD simulations
of the relevant complexes. At variance with other studies
reported in the literature, in this work we adopted an alterna-
tive approach based on a combination of steered molecular
dynamics (SMDs) and classical MD experiments to determine
the initial geometries of each dendrimer/ODN complex.
Specifically, starting from a common initial configuration,
each dendrimer was guided towards three diﬀerent regions of
the ODN (i.e., the two ends and the center of the ODN
sequence) by SMD simulations and, once a distance of
approximately 12 Å was achieved, each configuration was
allowed to evolve to equilibrium by classical MD simulation
runs. Fig. 5 illustrated this procedure taking dendrimer 4 and
the ODN GEM91 as examples. As can be seen from the images
in Fig. 5, independently of the initial binding region the ODN
is completely wrapped around the dendrimer and the resulting
complexes become virtually indistinguishable at the end of
each combined MD process. Analogous results were obtained
with all dendrimers and with both ODN sequences.
To quantitatively substantiate the equivalence of the three
final structures, we compared the distance between the dendri-
mer/ODN centers of mass (COM) and the radial monomer dis-
tributions ρ(r) of the corresponding complexes, as illustrated
in Fig. 6 taking again the complex between 4 and GEM91 as an
example. The left panel in Fig. 6 shows that, when the dendri-
mer/ODN binding process is started from a configuration
where, at the end of the SMD part, the dendrimer docks into
the center of the nucleic acid single strand, a very short time is
required for the ODNs to wrap around the dendrimers; accord-
ingly, the COM distance of the relevant complexes readily
reach their equilibrium value (7 Å on average, Fig. 6). When
the dendrimers bind to either end of the ODN sequences, the
nucleic acid needs to overcome larger energetic and entropic
barriers in order to fold before it can find its wrapping around
the dendrimer surface.
This more complex folding pathway clearly requires longer
times, but in the end the COM distances between dendrimers
and ODNs do converge to the same equilibrium value (Fig. 6).
Also, rather importantly, the degree of ODN strand/dendrimer
compenetration, defined as the integral of the area shared by
the dendrimer and ODN ρ(r) curves (see the right panel of
Fig. 5 Coupling steered molecular dynamics (SMD) and classical MD
simulations to mimic the binding process of dendrimer 4 to the ODN
GEM91 (see the text for more details). The dendrimer is portrayed as
dark lavender spheres while the ODN strand is represented as an orange
ribbon. Water and oxygen atoms are shown as transparent aqua spheres,
whereas some Na+ and Cl− ions are portrayed as gray and cyan spheres,
respectively.
Fig. 4 Monomer density distribution ρ(r) for the G2 carbosilane dendri-
mers 1–4. Color legend: 1, light blue; 2, dark sea green; 3, plum; 4, dark
lavender.
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Fig. 6), is very similar in the three cases of Fig. 5, being equal
to 72.1%, 75.5%, and 72.9%, respectively.
Conclusive proof of the equivalence of the dendrimer/ODN
final complex structures produced by the combined SMD/MD
approach can be found in the corresponding values of the free
energy of binding ΔGbind, as calculated via the MM/PBSA
ansatz. Referring again to the GEM91/4 assembly as an
example (see Table SI1† for all other cases), the ΔGbind values
calculated for the two equilibrated complex structures having
the dendrimer initial position at one extreme of the ODN
strand (e.g., the bottom panel in Fig. 5, right and left images)
are −53.4 ± 4.6 kcal mol−1 and −53.3 ± 5.1 kcal mol−1, respecti-
vely, while for the complex originating from the assembly
featuring the dendrimer centrally with respect to the ODN
strand (bottom panel, central in Fig. 5 central image) ΔGbind =
−54.9 ± 5.0 kcal mol−1. It is evident that, also from an ener-
getic standpoint, the three structures are indeed comparable,
the diﬀerence in the aﬃnity between the dendrimer and ODN
being within the relevant ΔGbind standard deviation intervals.
Of note, utterly similar results are obtained for all other
dendrimers, both in complex with GEM91 and SREV.
Given the structural equivalence of the three, final equili-
brated structures of each dendrimer/ODN complex, all the
remaining discussions will be focused on one single structure
only, i.e. the one generated from SMD experiments placing the
dendrimer central to the nucleic acid strand.
Structural aspects of the complexes
Fig. 7 and SI2† oﬀer a zoomed view of the equilibrated struc-
tures of each ODN/dendrimer conformation.
From these images we can observe how, independently of
the positive charge content of the dendrimers, the ODN not
only wraps around them but we also see a significant compe-
netration of the two molecular entities. To quantify this picto-
rial evidence, Table 2 lists the values of some important
structural parameters extracted from the analysis of the equili-
brated MD trajectory of all dendrimer/ODN complexes.
A swift survey of the values shown in Table 2 reveals that
the G2 carbosilane dendrimers 1–4 do not change the size and
shape upon binding to the ODNs. Indeed, both Rg and δ
values for the dendrimers in the complexes are virtually indis-
tinguishable from those of the dendrimers alone (Tables 1 and
2, see also Fig. SI3†). In line with this, Fig. 8 shows the time
evolution of the radius of gyration Rg of the ODN GEM91 in
complex with dendrimers 1–4 as an example.
However, some diﬀerences between the dendrimer com-
plexes with GEM91 and those involving SREV begin to appear.
First, the values of the dendrimer/ODN interface areas (INT)
Fig. 7 Equilibrated MD snapshots of dendrimers 1–4 in complex with
the ODN GEM91. Dendrimers 1 (A), 2 (B), 3 (C), and 4 (D) are depicted as
light sky blue, dark sea green, plum, and dark lavender sticks and balls,
respectively, with terminally charged amine groups highlighted in green.
The GEM91 sequence is portrayed as an orange ribbon. Water and ions
are omitted for clarity.
Table 2 Radius of gyration Rg (Å), asphericity δ (−), interface area
between the dendrimer and ODN INT (Å2), and the average number of
contacts between the dendrimer positively charged nitrogen atoms and
the ODN negatively charged oxygen atoms Nc (−) for dendrimers 1–4 in
complex with GEM91 and SREV ODNs
GEM91
Rg δ INT Nc
1 9.16 ± 0.11 0.0128 233 ± 32 6.1 ± 0.2
2 10.46 ± 0.12 0.0099 709 ± 46 9.7 ± 0.2
3 9.99 ± 0.10 0.0185 1723 ± 53 15.2 ± 0.3
4 10.71 ± 0.11 0.0107 1953 ± 62 17.2 ± 0.3
SREV
Rg δ INT Nc
1 9.13 ± 0.12 0.0150 194 ± 29 5.7 ± 0.3
2 10.42 ± 0.10 0.0102 515 ± 38 7.9 ± 0.2
3 9.87 ± 0.11 0.0188 1762 ± 51 15.5 ± 0.4
4 10.70 ± 0.11 0.0108 1878 ± 66 15.5 ± 0.3
Fig. 6 (left) Center of mass (COM) distance between dendrimer 4 and
the ODN GEM91 as a function of time for the three, diﬀerent initial
binding positions: light and medium lavender, dendrimer initially bound
by SMD at the ends of the ODN strand; dark lavender, dendrimer initially
bound by SMD in the middle of the ODN sequence. (right) Radial
monomer distribution of dendrimer 4 and GEM91 of the three ﬁnal,
equilibrated complex structures. Color legend: light lavender (4)/light
orange (ODN) and medium lavender (4)/medium orange (ODN): MD
equilibrated conﬁguration obtained from the dendrimer initially bound
by SMD at the ends of the ODN strand; dark lavender (4)/dark orange
(ODN): MD equilibrated conﬁguration obtained from the dendrimer
initially bound by SMD in the middle of the ODN strand.
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within the complexes (Table 2) are diﬀerent between the
diﬀerent dendrimers and, for a given dendrimer, between
GEM91 and SREV.
Specifically, for both ODNs INT monotonically increases in
passing from 1 to 4, although the diﬀerence in INT values pro-
gressively levels oﬀ between dendrimers 3 and 4. Also, the INT
values are lower for all dendrimers in complex with SREV with
respect to the GEM91 complex counterparts (Table 2). In
keeping with this, also the number of contacts between the
positively charged nitrogen atoms on the dendrimers and the
negatively charged oxygen atoms of the ODN phosphate
groups Nc follows the same trend: Nc increases from 1 to 4 and
is larger (on average) for GEM91 with respect to SREV
(Table 2). In keeping with these results, the values of Rg for the
GEM91/dendrimer complexes are slightly lower than those of
the SREV counterparts (Table 3), suggesting a smaller degree
of penetration and, hence, somewhat weaker interactions
between the G2 carbosilane dendrimers and the SREV strand.
Considering the monomer density distribution of the den-
drimer/ODN complexes yields further information on the
structural features of these supermolecular assemblies. For the
purpose of discussion, Fig. 9 shows these distributions for
dendrimer 4 in complex with ODN GEM91.
Upon binding, the curve of the ODN single strand shows
the maximum in the location of the dendrimer terminal
groups, which roughly corresponds to the radius of gyration of
the dendrimers. Also, we distinctly see a substantial pene-
tration of the ODN within the dendrimer structure. However,
considering again the degree of compenetration of the ODN
strand and the dendrimer, diﬀerences among the diverse den-
drimers and between the two strands can be detected. In fact,
not only this parameter increases in going from dendrimer 1
to dendrimer 4 for a given ODN, but it also slightly decreases
in passing from GEM91 to SREV (in the order: 37.6% (1),
55.0% (2), 72.0% (3), and 75.7% (4) for GEM91 and 32.1% (1),
47.5% (2), 65.2% (3), and 73.7% (4) for SREV, respectively).
These pieces of evidence could be taken as the first, rough
indication that the interactions of the dendrimers with a given
ODN decrease in the order 4 ≥ 3 > 2 > 1 and that, for a given
dendrimer, more favorable interactions characterize the
complex with the ODN GEM91 than the assembly with ODN
SREV.
Energetical aspects of ODN/dendrimer binding
To substantiate these seemingly diﬀerent binding interactions
among the G2 carbosilane dendrimers 1–4 and the two single
strand nucleotide sequences GEM91 and SREV, we next pro-
cessed the data collected during equilibrated MD simulations
of the single molecular species and the relevant complexes in
the framework of the MM/PBSA theory. Specifically, we
assessed the eﬀective free energy of binding ΔGbind,eﬀ, that is
the contribution to binding yielded by the dendrimer branches
in constant and productive contact with the nucleic acid frag-
ment, as shown in Table 4 (see also Table SI3†). To estimate
ΔGbind,eﬀ for each dendrimer/ODN complex, all branches of
dendrimers 1–4 involved in ODN binding (Neﬀ, Table 4) were
Fig. 8 Evolution of the radius of gyration Rg of the ODN GEM91, the
dendrimers 1–4, and the relevant complexes showing the shape invari-
ance of the dendrimers and the conformational adaptation of the ODN
upon binding. (top left) 1, light blue; ODN GEM91, orange, complex,
dark blue; (top right) 2, dark sea green, ODN GEM91, orange, complex,
light sea green; (bottom left) 3, plum; ODN GEM91, orange; complex,
purple; (bottom right) 4, dark lavender, ODN GEM91 orange, complex,
light lavender.
Table 3 Radius of gyration Rg (Å) of the two ODNs GEM91 and SREV
wrapped around the dendrimers 1–4 and of the relevant complexes
GEM91 SREV
ODN Complex ODN Complex
1 15.83 ± 0.55 15.44 ± 0.49 1 17.28 ± 0.28 15.69 ± 0.21
2 15.57 ± 0.36 15.00 ± 0.27 2 16.12 ± 0.23 15.50 ± 0.20
3 13.87 ± 0.25 14.34 ± 0.50 3 15.20 ± 0.19 14.44 ± 0.17
4 13.71 ± 0.50 13.98 ± 0.30 4 14.95 ± 0.25 14.20 ± 0.20
Fig. 9 Density distribution ρ(r) for the dendrimers 1–4 and the ODN
GEM91 in the relevant complexes. Top left, 1; top right, 2; bottom left, 3;
bottom right 4. Dendrimer and ODN curves are represented by conti-
nuous and broken lines, respectively.
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precisely identified (see Fig. 1) and their individual contri-
bution towards the overall binding energy estimated via a per
residue deconvolution of the binding free energy (Table SI2†).
The first, interesting finding of this analysis concerns a
number of dendrimer branches eﬃciently involved in binding
the two ODNs. Indeed, in both ODN complexes the G2 carbosi-
lane dendrimer 1 has the smallest number of branches in
contact with the nucleic acid (Neﬀ = 6), while the remaining
three dendrimers have more branches (8/9, Table 4) eﬀectively
involved in ODN binding. Contextually, ΔGbind,eﬀ is larger (i.e.,
more negative and, hence, more favorable) for dendrimers 2–4
with respect to dendrimer 1, in both series of complexes
(Table 4). Normalizing ΔGbind,eﬀ by Neﬀ yields the performance
of the diﬀerent dendrimers in using each active individual
branch directly involved in a binding interaction (ΔGbind,eﬀ/Neﬀ,
Table 4). As we see, ΔGbind,eﬀ/Neﬀ increases substantially in
passing from dendrimer 1 to dendrimer 4 for both ODN com-
plexes, the diﬀerence between dendrimers leveling oﬀ between
dendrimers 3 and 4. Also, from data in Table 1 a small
eﬃciency in binding GEM91 with respect to SREV can be
envisaged.
The diﬀerential eﬃcacy in binding the ODNs shown by the
four G2 carbosilane dendrimers finds its molecular roots in
the diverse number and type of interaction each dendrimer
branch is able to establish with the nucleic acid. As shown in
Table 5, independently of their structural details and their
charge, all dendrimers exploit a conspicuous number of salt
bridges between the terminal, positively charged nitrogen of
the dendrimer atoms and the negatively charged oxygens of
the ODN phosphate groups (see, for instance, Fig. 10, panels A
and B).
However, the presence of a second N atom in the dendrimer
branches as in dendrimers 3 and 4 allows for further intermo-
lecular interactions, the nature and number of which depend
on that atom being electrically neutral (3) or positively charged
(4). Indeed, a number of H-bonds are generated within each
ODN/dendrimer complex in the case of 3 (Table 5 and
Fig. 10C), which justifies the higher eﬃcacy of these dendri-
mer branches in ODN binding and, consequently, the greater
stabilization of the relevant complex with respect to those
made from 1 and 2 (Table 4). When this N atom bears a neat,
positive charge as in 4, beside the salt-bridges and some
H-bonds, we detect the unsaturation of a number of permanent
π–cation interactions involving this quaternary nitrogen and
the aromatic rings of the nucleic bases, as shown in Fig. 10D.
These interactions are quite strong and, hence, contribute to
the higher eﬃciency of per residue (as well as overall) ODN
aﬃnity of G2 carbosilane dendrimer 4.
Table 4 Predicted number of eﬀective dendrimer branches Neﬀ (−),
eﬀective free energy of binding ΔGbind,eﬀ (kcal mol−1), and normalized
eﬀective free energy of binding ΔGbind,eﬀ/Neﬀ (kcal mol−1) for dendri-
mers 1–4 in complex with the two ODN sequences GEM91 and SREV
GEM91
Neﬀ ΔGbind,eﬀ ΔGbind,eﬀ/Neﬀ
1 6 −11.9 ± 1.4 −2.0 ± 0.2
2 9 −23.9 ± 2.1 −2.7 ± 0.2
3 8 −34.6 ± 2.9 −4.3 ± 0.4
4 8 −45.9 ± 3.6 −5.7 ± 0.5
SREV
Neﬀ ΔGbind,eﬀ ΔGbind,eﬀ/Neﬀ
1 6 −11.3 ± 0.8 −1.9 ± 0.1
2 9 −22.0 ± 2.0 −2.4 ± 0.2
3 8 −32.2 ± 4.2 −4.0 ± 0.5
4 8 −43.1 ± 4.3 −5.4 ± 0.5
Fig. 10 Zoomed view of the diﬀerent intermolecular interactions
between the G2 carbosilane dendrimers 1–4 and the ODN GEM91, as
detected in the equilibrate portion of the corresponding MD trajectories.
Dendrimers 1 (A), 2 (B), 3 (C), and 4 (D) are depicted as transparent sticks
and balls, the terminal residues involved in ODN binding colored by the
element. The GEM91 strand is portrayed as transparent sticks. Each non-
covalent interaction (salt-bridges, H-bonds, and π–cation interactions) is
highlighted by a dotted black line. Water and ions are omitted for clarity.
Table 5 The type and number of intermolecular interactions between
dendrimers 1–4 and the two ODN sequences GEM91 and SREV as
detected in the corresponding equilibrated MD trajectories
GEM
Salt bridge H-bond π–cation
1 6 — —
2 9 — —
3 8 8 —
4 8 3 5
SREV
Salt bridge H-bond π–cation
1 6 — —
2 9 — —
3 8 8 —
4 8 4 4
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The free energy analysis described above allows for several,
further comments. First, the diﬀerent lengths of the dendri-
mer branches between molecules 1 and 3 reflect in a consider-
ably higher eﬃciency of the latter dendrimer to bind both
ODNs: thus, ΔGbind,eﬀ/Neﬀ = −2.0 and −1.9 kcal mol−1 for 1 in
complex with GEM91 and SREV while ΔGbind,eﬀ/Neﬀ = −4.3 and
−4.0 kcal mol−1 for 3 bound to the same two nucleotide
sequences, respectively (Table 4). At the same time, doubling
the number of branching – and hence the number of positive
charges – in passing from 1 to 2 reflects only in a modest,
although not negligible, increase in ODN aﬃnity. That is to
say, the architecture of the dendrimer branches rather than
the dendrimer overall charge seems to be a fundamental par-
ameter for eﬀective ODN binding in this series of G2 carbosi-
lane dendrimers. Comparing now the performance of
dendrimers 2 and 4, both with the overall charge +16, high-
lights the importance of another molecular architecture para-
meter, that is the location of the charges within the
molecular structure. In fact, according to the present calcu-
lations, having 2 positive charges on the same branch as in 4
(Fig. 1) is far more eﬃcient as concerns ODN binding than
having 2 positive charges on two vicinal branches, as in 2
(Fig. 1). Indeed, the architecture of dendrimer 4 allows, aside
from the ever-present salt bridges, the realization of other
intermolecular dendrimer/ODN contacts such as H-bonds and
π–cation interactions (Table 5) within the supermolecular
complex. These, in turn, make dendrimer 4 not only dramati-
cally more eﬀective in binding the ODNs with respect to 2
(ΔGbind,eﬀ/Neﬀ = −2.7 and −2.4 kcal mol−1 for 2 in complex
with GEM91 and SREV while ΔGbind,eﬀ/Neﬀ = −5.7 and 5.4 kcal
mol−1 for 4 in complex with the same ODNs, Table 4), but also
make this molecule the best binder of the entire series. Lastly,
it is instructive to compare dendrimers 3 and 4. Indeed, these
two molecules present the same molecular architecture but
they diﬀer by the number of positive charges (+8 and +16,
respectively). Thus, while the tertiary nitrogen atoms characteri-
zing the branches of 3 are involved in a plethora of permanent,
stabilizing H-bonds with the nucleic acid bases, making this
dendrimer a good ODN binder, the inner quaternary nitrogens
of 4 are engaged in several π–cation interactions (Table 5),
which decidedly enhance the aﬃnity of these dendrimer
branches toward the nucleic acid strand (ΔGbind,eﬀ/Neﬀ = −4.3
and −4.0 kcal mol−1 for 3 bound to GEM91 and SREV and
ΔGbind,eﬀ/Neﬀ = −5.7 and −5.4 kcal mol−1 for 4 in complex with
the same ODNs).
Conclusions
Insuﬃcient concentrations and very short residence time of
the anti-retroviral agents at the cellular and anatomical sites
are among the major factors that contribute to the failure of
eradicating HIV from reservoirs and the development of multi-
drug resistance against antiretroviral agents. Gene therapy
oﬀers the promise of preventing progressive HIV infection by
sustained interference with viral replication in the absence of
chronic chemotherapy. Accordingly, gene-targeting strategies
are being developed with RNA-based agents, such as ribo-
zymes, antisense oligonucleotides, and small interfering RNA,
just to name a few. Yet, to date, gene therapy targeting
HIV-1 has not fulfilled its promises and hopes. Nonetheless,
there is considerable motivation to be optimistic about its
future for HIV-1 therapeutics as analysis of unsuccessful anti-
HIV-1 gene therapy studies is providing fundamental insights
for improvements. One of the major reasons of such failure
resides in the fact that, to reach the therapeutic goal of gene
delivery, the use of nanocarriers able to reach the desired
population of cells avoiding all biological barriers is inelucta-
bly required.
It is estimated that several hundreds of diﬀerent nanovec-
tors are in various stages of pre-clinical and clinical develop-
ment toward regulatory approval in the USA and worldwide.
These nano-sized molecular entities have the primary function
of transporting the active agent to the target site, performing
the multiple biobarrier-avoidance tasks required along the
way. To perform these ambitious tasks, however, nanovectors
must be carefully designed and engineered to employ several,
concurrent strategies to localize preferentially at the target
cells, and release its therapeutic payload.
G2 cationic carbosilane dendrimers 1–4 have been shown
to hold great potential as gene carriers for HIV-1 treatment
both in vitro and in vivo. In particular, the characterization of
ODN binding properties of these dendrimers has highlighted
a diﬀerential aﬃnity for nucleic acid strands notwithstanding
a remarkable similarity in structure and overall charge content
of the members of this molecular series. Since the detailed
knowledge of structure/activity relationships governing the per-
formance of these nano-objects is the ultimate tool for (i)
understanding the reasons of their success/failure and (ii)
designing new, more eﬃcient, second generation nanovectors,
in this work we aimed at unraveling a molecular rationale for
the diﬀerent ODN binding capacity of four G2 carbosilane den-
drimers. To the purpose, we performed a thorough in silico
characterization of the structural and energetical features of
G2 carbosilane dendrimers 1–4, and their complexes with the
two single strands ODN GEM91 and SREV. Our results show
that these four dendrimers are all characterized by utterly
similar shape and size, independently of their molecular archi-
tecture or overall molecular charge, and so are the relevant
complexes with the nucleic acids. On the other hand, depend-
ing on the molecular architecture and/or the disposition of the
positive charges within the molecular scaﬀold, these mole-
cules display a remarkably diﬀerent capacity of exploiting their
charged groups for binding the negative ODNs in an eﬃcient
and productive way. Accordingly, the diﬀerent ODN binding
aﬃnity of dendrimers 1–4 has been rationalized considering
the normalized eﬀective binding energy ΔGbind,eﬀ/Neﬀ, i.e. the
performance of each active individual dendrimer branch
directly involved in a binding interaction. We have thus shown
that diﬀerent combinations of charge localization/molecular
architecture reflect, upon dendrimer/ODN complex formation,
in the intermolecular interaction of diﬀerent nature and
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strength; this, in turn, makes some molecules more eﬃcient
ODN binders than others. Furthermore, this study conclusively
shows that normalized eﬀective binding energy plays a domi-
nant role among the plethora of critical molecular parameters
requiring optimization in the design of eﬃcient nanovectors
for gene therapy.
Acknowledgements
COST Action TD0802 is acknowledged for scientific network
support. Access to CINECA supercomputers Eurora and Fermi
(Bologna, Italy) was granted via DILUSO and SYMBIOSI pro-
jects (Iscra supercomputing grants to DM and SP).
Notes and references
1 M. L. Ehterige, S. A. Campbell, A. G. Erdman, C. L. Haynes,
S. M. Wolf and J. McCullough, Nanomedicine, 2013, 9, 1;
E. K.-H. Chow and D. Ho, Sci. Transl. Med., 2013, 5, 216rv4;
R. Lehner, X. Wang, S. Marsh and P. Hunziker, Nanomedi-
cine, 2013, 9, 742; V. J. Venditto and F. C. Szoka Jr., Adv.
Drug Delivery Rev., 2013, 65, 80; R. Duncan and R. Gaspar,
Mol. Pharm., 2011, 8, 2010; B. Y. S. Kim, J. T. Rutka and
W. C. W. Chan, N. Engl. J. Med., 2010, 363, 2434; M. Ferrari,
Nat. Rev. Cancer, 2005, 5, 161.
2 A. M. Jhaveri and V. P. Torchilin, Front. Pharmacol., 2014, 5,
1; J. Nicolas, S. Mura, D. Brambilla, N. Mackievicz and
P. Couvreur, Chem. Soc. Rev., 2013, 42, 1147; B. Godin,
E. Tasciotti, X. Liu, R. E. Serda and M. Ferrari, Acc. Chem.
Res., 2011, 44, 979.
3 M. Moros, S. G. Mitchell, V. Grazù and J. M. de la Fuente,
Curr. Med. Chem., 2013, 20, 2759; Q. Sun, M. Radosz and
Y. Shen, J. Controlled Release, 2012, 164, 156.
4 S. Svenson, Mol. Pharm., 2013, 10, 848.
5 C. M. Dawidczyk, C. Kim, J. H. Park, L. M. Russell,
K. H. Lee, M. G. Pomper and P. C. Searson, J. Controlled
Release, 2014, 187C, 133.
6 S. Y. Wu, G. Lopez Berestein, G. A. Calin and A. K. Socol,
Sci. Transl. Med., 2014, 6, 240ps7; H. Shen and M. Ferrari,
Cancer Gene, 2012, 19, 367; J. R. Viola, S. El-Andaloussi,
I. I. Oprea and C. L. Smith, Expert Opin. Drug Deliv., 2010,
7, 721.
7 J. Wu, W. Huang and Z. He, Sci. World J., 2013, 630654;
D. Shcharbin, A. Shakhbazau and M. Bryszewska, Expert
Opin. Drug Deliv., 2013, 10, 1687; M. A. Mintzer and
M. W. Grinstaﬀ, Chem. Soc. Rev., 2011, 40, 173.
8 G. Maartens, C. Celum and S. R. Lewin, Lancet, 2014, 384,
258.
9 Y. Deng, C. C. Wang, K. W. Choy, Q. Du, J. Chen, Q. Wang,
L. Li, T. K. Chung and T. Tang, Gene, 2014, 538, 217;
A. A. Date and C. J. Destache, Biomaterials, 2013, 34, 6202.
10 J. P. Dassie and P. H. Giangrande, Ther. Delivery, 2013, 4,
1527; J. Zhou and J. J. Rossi, BioDrugs, 2012, 26, 393.
11 M. Dirin and J. Winkler, Expert Opin. Biol. Ther., 2013, 13,
875.
12 A. J. Perisé-Barrios, J. L. Jiménez, A. Domínguez-Soto,
F. J. de la Mat, A. L. Corbí, R. Gomez and M. A. Muñoz-
Fernandez, J. Controlled Release, 2014, 184, 51;
E. Pedziwiatr-Werbicka, E. Fuentes, V. Dzmitruk,
J. Sánchez-Nieves, M. Sudas, E. Drozd, A. Shakhbazau,
D. Shcharbin, F. J. de la Mata, R. Gomez-Ramirez,
M. A. Munoz-Fernandez and M. Bryszewska, Colloids Surf.,
B, 2013, 109, 183; E. Pedziwiatr-Werbicka, D. Shcharbin,
J. Maly, M. Maly, M. Zaborski, B. Gabara, P. Ortega, J. F. de
la Mata, R. Gómez, M. A. Muñoz-Fernandez, B. Klajnert
and M. Bryszewska, J. Biomed. Nanotechnol., 2012, 8, 57;
E. Pedziwiatr, D. Shcharbin, L. Chonco, P. Ortega, F. J. de
la Mata, R. Gómez, B. Klajnert, M. Bryszewska and
M. A. Muñoz-Fernandez, J. Fluoresc., 2009, 19, 267;
L. Chonco, J. F. Bermejo-Martín, P. Ortega, D. Shcharbin,
E. Pedziwiatr, B. Klajnert, J. F. de la Mata, R. Eritja,
R. Gómez, M. Bryszewska and M. A. Muñoz-Fernandez,
Org. Biomol. Chem., 2007, 5, 1886; J. F. Bermejo, P. Ortega,
L. L. Chonco, R. Eritja, R. Samaniego, M. Müllner, E. de
Jesus, J. F. de la Mata, J. C. Flores, R. Gomez and
M. A. Munoz-Fernandez, Chem. – Eur. J., 2007, 13, 483;
P. Ortega, J. F. Bermejo, L. Chonco, E. de Jesus, J. F. de la
Mata, G. Fernández, J. C. Flores, R. Gómez, M. J. Serramía
and M. A. Munoz-Fernandez, Eur. J. Inorg. Chem., 2006,
1388.
13 D. Shcharbin, E. Pedziwiatr, L. Chonco, J. F. Bermejo-
Martín, P. Ortega, F. J. de la Mata, R. Eritja, R. Gómez,
B. Klajnert, M. Bryszewska and M. A. Muñoz-Fernandez,
Biomacromolecules, 2007, 8, 2059.
14 D. A. Case, V. Babin, J. T. Berryman, R. M. Betz, Q. Cai,
D. S. Cerutti, T. E. Cheatham III, T. A. Darden, R. E. Duke,
H. Gohlke, A. W. Goetz, S. Gusarov, N. Homeyer,
P. Janowski, J. Kaus, I. Kolossváry, A. Kovalenko, T. S. Lee,
S. LeGrand, T. Luchko, R. Luo, B. Madej, K. M. Merz,
F. Paesani, D. R. Roe, A. Roitberg, C. Sagui, R. Salomon-
Ferrer, G. Seabra, C. L. Simmerling, W. Smith, J. Swails,
R. C. Walker, J. Wang, R. M. Wolf, X. Wu and
P. A. Kollman, AMBER 14, University of California,
San Francisco, 2014.
15 G. M. Pavan, P. Posocco, A. Tagliabue, M. Maly, M. Malek,
A. Danani, E. Ragg, C. V. Catapano and S. Pricl,
Chem. – Eur. J., 2010, 16, 7781.
16 J. Wang, R. M. Wolf, J. W. Caldwell, P. A. Kollman and
D. A. Case, J. Comput. Chem., 2004, 25, 1157.
17 M. W. Schmidt, K. K. Baldridge, J. A. Boatz, S. T. Elbert,
M. S. Gordon, J. H. Jensen, S. Koseki, N. Matsunaga,
K. A. Nguyen, S. Su, T. L. Windus, M. Dupuis and
J. A. Montgomery, J. Comput. Chem., 1993, 14, 1347;
M. S. Gordon and M. W. Schmidt, Advances in electronic
structure theory: GAMESS a decade later, in Elsevier (Ed.)
Theory and Applications of Computational Chemistry: the first
forty years, Elsevier, Amsterdam, 2005, pp. 1167–1189.
18 J.-H. Lii and N. L. Allinger, J. Comput. Chem., 1991, 12,
186.
Nanoscale Paper

























19 W. L. Jorgensen, J. Chandrasekhar, J. D. Madura,
R. W. Impey and M. L. Klein, J. Chem. Phys., 1983, 79,
926.
20 J.-P. Ryckaert, G. Ciccotti and H. J. C. Berendsen, J. Comput.
Phys., 1977, 23, 327.
21 X. Wu and B. R. Brooks, Chem. Phys. Lett., 2003, 381, 512.
22 H. J. C. Berendsen, J. P. M. Postma, W. F. van Gunsteren,
A. DiNola and J. R. Haak, J. Chem. Phys., 1984, 81,
3684.
23 T. Darden, D. York and L. Pedersen, J. Chem. Phys., 1993,
98, 10089.
24 E. Laurini, P. Posocco, M. Fermeglia, D. L. Gibbons,
A. Quintas-Cardama and S. Pricl, Mol. Oncol., 2013, 7, 968;
S. Park and K. Schulten, J. Chem. Phys., 2004, 120, 5946;
S. Park, F. Khalili-Araghi, E. Tajkhorshid and K. Schulten,
J. Chem. Phys., 2003, 119, 3559; B. Isralewitz, J. Baudry,
J. Gullingsrud, D. Kosztin and K. Schulten, J. Mol. Graphics
Modell., 2001, 19, 13.
25 J. Srinivasan, T. E. Cheatham, P. Cieplak, P. A. Kollman
and D. A. Case, J. Am. Chem. Soc., 1998, 120, 9401.
26 A. Onufriev, D. Bashford and D. A. Case, J. Phys. Chem. B,
2000, 104, 3712.
27 M. Feig, A. Onufriev, M. S. Lee, W. Im, D. A. Case and
C. L. Brooks III, J. Comput. Chem., 2004, 25, 265.
28 P. K. Maiti, T. Cagin, S.-T. Lin and W. A. Goddard III,
Macromolecules, 2005, 38, 979; P. K. Maiti, T. Cagin,
G. Wang and W. A. Goddard III, Macromolecules, 2004, 37,
6236.
29 G. Rudnick and G. Gaspari, J. Phys. A: Math. Gen., 1986, 4,
L191.
30 D. A. Tomalia, A. M. Naylor and W. A. Goddard III, Angew.
Chem., Int. Ed. Engl., 1990, 29, 138.
Paper Nanoscale
12 | Nanoscale, 2014, 00, 1–12 This journal is © The Royal Society of Chemistry 2014
1
5
10
15
20
25
30
35
40
45
50
55
1
5
10
15
20
25
30
35
40
45
50
55
